Revenue Growth and Integration Success
Delivered on revenue expectations with $40 million in Q3, marking a 12% year-over-year increase. Successfully integrated Akoya, realizing $67 million of the $85 million in targeted synergies.
Strong Cash Position
On track to finish the year with approximately $120 million in cash and no debt, supported by improved working capital and cost reductions from integration activities.
Early Success in Alzheimer's Diagnostics
Received a positive pricing recommendation for LucentAD test at $897. Added 4 diagnostics partners in Asia, expanding reach and availability of high sensitivity biomarker testing.
Early Commercial Momentum and Cross-Selling Opportunities
Significant early interest in combining tissue and blood insights, with noted cross-selling opportunities between Simoa and Spatial portfolios.